Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.45 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972588 | 0.91 | PPARG (0.48) | PPARGMAPTFFAR1THRATHRB | |
| Hydrochloric Acid SCHEMBL3965265 | 0.90 | PPARG (0.47) | PPARGMAPTFFAR1THRATHRB | |
| SCHEMBL6247519 | 0.90 | PPARG (0.43) | MMEACECPA1ACE2PPARG | |
| SCHEMBL3966198 | 0.89 | FFAR1 (0.49) | MMEACECPA1ACE2PPARG | |
| SCHEMBL3965669 | 0.86 | PPARG (0.42) | MMEACECPA1ACE2PPARG | |
| SCHEMBL3968290 | 0.86 | FFAR1 (0.50) | PPARGMAPTFFAR1PPARAMEN1 | |
| SCHEMBL15844982 | 0.86 | PPARG (0.51) | PPARGMAPTFFAR1THRATHRB | |
| SCHEMBL3972724 | 0.85 | PPARG (0.45) | MMEACECPA1ACE2PPARG | |
| Hydrochloric Acid SCHEMBL4158143 | 0.85 | PPARG (0.50) | PPARGMAPTFFAR1THRATHRB | |
| SCHEMBL13875934 | 0.84 | PPARG (0.52) | PPARGMAPTFFAR1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087576-B2 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | claimed |
| WO-2005034981-A1 | DIPEPTIDE PHENYL ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | claimed |
| US-20050075293-A1 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | claimed |
| US-7521466-B2 | Dipeptide phenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | NAG BISHWAJIT | 2007-02-15 | — | — | US | disclosed |
| US-7087576-B2 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050075293-A1 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075293-A1 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | DPP4, GPR119, IAPP | MME 128/4885ACE 492/4885CPA1 1481/4885 |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | FFAR4, IAPP, FFAR2 | MME 470/4885ACE 1104/4885CPA1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.